Research
Metabolic adaptation
Placebo-adjusted weight loss was significantly lower in T2D versus obesity trials (pooled ratio: 0.61, 95% C.I. 0.56; 0.67).
Clinicians should consider that patients with T2D may experience less weight loss from incretin therapies compared to those with obesity alone.
StrongSupportsmedium confidence
Placebo-adjusted weight loss was significantly lower in T2D versus obesity trials (pooled ratio: 0.61, 95% C.I. 0.56; 0.67).
Why this rating
Based on a meta-regression of multiple RCTs.
Source
Rethinking diabetes as a modifier of the weight-loss response to incretin-based therapies. A twin trial meta-regression
Marella Marassi et al. · Nutrition Metabolism and Cardiovascular Diseases · 2026
DOI 10.1016/j.numecd.2026.104714
Meta-analysis
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Study-level diabetes status, age, BMI, sex distribution, ethnicity, and cardiometabolic comorbidities significantly correlated with BW loss at univariate analysis.Strong
- Adjustment for covariates differing between trial type and associated with BW reduction nullified the association between T2D status and weight loss (p = 0.93).Strong
Related findings · Metabolic adaptation
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →